Assessing the effects of naltrexone‐bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo‐controlled trial

Documenti analoghi

• Characterization of the effect of naltrexone/bupropion on body composition
  di: Vanessa Tardio, et al.
  Pubblicazione: (2025)
• Total and H‐specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration
  di: Sofia K. Konstantinidou, et al.
  Pubblicazione: (2024)
• The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review
  di: Sean Wharton, et al.
  Pubblicazione: (2024)
• Effect of concurrent training on risk factors and hepatic steatosis in obese adolescents
  di: Barbara de Moura M. Antunes
  Pubblicazione: (2013)
• Prevalence of hepatic steatosis and fibrosis in Turner syndrome: A prospective case–control study
  di: Patrick Twohig, et al.
  Pubblicazione: (2024)